摘要:

ObjectiveTo determine factors associated with acute respiratory failure after bone marrow transplantation which can be identified before the onset of lung disease.DesignPopulation-based, retrospective study.SettingA referral-based pediatric intensive care unit and bone marrow transplant center.PatientsThirty-nine patients with lung disease (abnormal chest radiograph or a need for supplemental oxygen) were identified from a group of 318 pediatric bone marrow transplant patients from 1978 to 1988. Thirty-four of 39 patients with complete data were further classified into patients with mild lung disease (recovery without needing endotracheal intubation, n = 16) and patients with acute respiratory failure (requirement for endotracheal intubation, n = 18).InterventionsRegression analyses were performed to define risk factors for development of respiratory failure (multivariate logistic regression) and for a shortened interval between the identification of lung disease and respiratory failure (Cox proportional hazards analysis).Measurements and Main ResultsNinety-three percent (15/16) of patients with mild lung disease survived. Conversely, only 9% (2/23) of patients with respiratory failure survived. Predictors of respiratory failure included graft vs. host disease (odds ratio 28.3, 95% confidence interval 1.9–421,p= .015), a prelung disease (baseline) circulating creatinine concentration of >1.5 mg/dL (>132.6 μmol/L) (odds ratio 28.4, 95% confidence interval 1.4–577,p= .029), and male gender (odds ratio 14.6, 95% confidence interval 1–210,p= .049). Predictors of a shortened time to onset of respiratory failure included baseline serum creatinine value of >1.5 mg/dL (>132.6 μmol/L) (hazard ratio 6.2, 95% confidence interval 1.5–26.5,p= .013) and baseline total bilirubin concentration >1.4 mg/dL (>23.9 μmol/L) (hazard ratio 4.5, 95% confidence interval 0.98–20.7,p= .053). The median time to onset of respiratory failure was 4 days in patients with baseline creatinine values ≥1.5 mg/dL (>132.6 μmol/L) and 5 days in patients with baseline bilirubin concentrations ≥;1.4 mg/dL (>23.9 μmol/L) vs. >26 days in patients with creatinine <1.5 mg/dL (<132.6 μmol/L) and >29 days in patients with bilirubin <1.4 mg/dL (<23.9 μmol/L) (Kaplan-Meier analysis).ConclusionsRenal and liver dysfunction preceded clinical evidence of lung disease in bone marrow transplant patients who developed respiratory failure. Lung disease leading to respiratory failure and adult respiratory distress syndrome appears to develop as one component of the multiple organ failure syndrome in pediatric bone marrow transplant patients.

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

摘要:

ObjectiveTo compare the sedative recovery rate pharmacology of intravenous midazolam vs. diazepam when used for short-term sedation.Data SourcesEnglish-language articles were identified through a search of the MEDLINE and InPharma databases. Bibliographies of retrieved articles were examined for relevant articles.Study SelectionTwenty-eight studies were identified based ona prioriinclusion criteria. Eight trials had enough information to combine results for sedative recovery rate.Data ExtractionThe difference in mean time to sedative recovery, weighted by sample size, was determined.Data SynthesisOf the 28 trials, eight reported a significantly faster sedation recovery rate from diazepam vs. midazolam, whereas 19 trials reported no difference in sedative recovery time, and a single trial reported that midazolam offered significantly faster recovery from sedation than diazepam. A commonly defined time to sedative recovery event was available for only eight trials. The median dosing ratio for these eight trials was 2.1:1 for diazepam over midazolam. The weighted mean time difference was 4 mins 16 secs in favor of diazepam as the agent from which patients recover more quickly.ConclusionsThese results firmly underscore the understanding that elimination half-lives of benzodiazepines do not necessarily correspond with their sedative pharmacodynamic effects, and we conclude that there are no clinically important sedative recovery rate differences between midazolam and diazepam, while midazolam is a more expensive agent. (Crit Care Med 1994; 22:1492–1496)

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:0090-3493    

出版商:OVID    

年代:1994

数据来源: OVID